Achillion leveraged its expertise in HCV drug discovery and structure-based design to create a set of compounds, including ACH-2684, that are part of a discrete intellectual property estate and to which Achillion currently retains all commercial rights.
Further demonstrating Achillions robust drug discovery expertise in this important therapeutic area, Achillion scientists discovered and optimized this compound at the Companys labs in New Haven. With its potency and resistance profile and preliminary safety characteristics, ACH-2684 has the potential to be highly complementary with other agents in an all-oral direct acting anti-viral treatment for HCV.
Achillion initiated a first-in-man Phase 1 study with ACH-2684 in May 2011 and anticipates proof-of-concept results near the end of 2011.
